Vor Biopharma Inc.
VOR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $3 | $9 | $0 |
| Gross Profit | $0 | -$3 | -$9 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $93 | $94 | $65 | $48 |
| G&A Expenses | $28 | $32 | $0 | $21 |
| SG&A Expenses | $28 | $32 | $20 | $21 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$3 | $0 | $0 |
| Operating Expenses | $121 | $123 | $84 | $69 |
| Operating Income | -$121 | -$126 | -$93 | -$69 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4 | $8 | $1 | $0 |
| Pre-Tax Income | -$117 | -$118 | -$92 | -$69 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$117 | -$118 | -$92 | -$69 |
| % Margin | – | – | – | – |
| EPS | -34 | -35 | -46.6 | -37.8 |
| % Growth | 2.9% | 24.9% | -23.3% | – |
| EPS Diluted | -34 | -35 | -46.6 | -37.8 |
| Weighted Avg Shares Out | 3 | 3 | 2 | 2 |
| Weighted Avg Shares Out Dil | 3 | 3 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $8 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $4 | $3 | $9 | $1 |
| EBITDA | -$118 | -$114 | -$83 | -$68 |
| % Margin | – | – | – | – |